var data={"title":"Gemcitabine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gemcitabine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6252?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">see &quot;Gemcitabine: Drug information&quot;</a> and <a href=\"topic.htm?path=gemcitabine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gemcitabine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175343\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gemzar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175344\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gemzar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016262\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite (Pyrimidine Antagonist)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016297\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">see &quot;Gemcitabine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Details concerning dosing in combination regimens should also be consulted. <b>Note:</b> Prolongation of the infusion time &gt;60 minutes and administration more frequently than once weekly have been shown to increase toxicity. Gemcitabine is associated with a low emetic potential risk (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting  (Basch 2011; Dupuis 2013; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin lymphoma, refractory or relapsed:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;10 years and Adolescents: IV: 1,000 mg/m<sup>2</sup>/dose over 100 minutes on days 1 and 8 (in combination with vinorelbine); repeat cycle every 21 days (Cole 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years: IV: 1,000 mg/m<sup>2</sup>/dose over 60 minutes on days 1, 8, and 15 (in combination with vinorelbine); repeat cycle every 28 days (Suyani 2011) <b>or</b> 800 mg/m<sup>2</sup>/dose on days 1 and 4 (in combination with ifosfamide and vinorelbine); repeat cycle every 21 days (Santoro 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sarcomas, refractory or relapsed (including Ewing sarcoma, osteosarcoma):</b> Limited data available: Children &ge;3 years and Adolescents: IV: 675 <b>or</b> 1,000 mg/m<sup>2</sup>/dose over 90 minutes on days 1 and 8 (in combination with docetaxel); repeat cycle every 21 days (Mora 2009; Navid 2008) <b>or</b> 1,000 mg/m<sup>2</sup>/dose over 30 minutes on days 1 and 8 (in combination with oxaliplatin and irinotecan); repeat cycle every 28 days (Hartmann 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid tumors, refractory or relapsed:</b> Limited data available: Children &ge;1 year and Adolescents: IV: 1,000 mg/m<sup>2</sup>/dose over 30 minutes on days 1 and 8 (in combination with oxaliplatin and irinotecan); repeat cycle every 28 days (Hartmann 2011) <b>or</b> 1,000 mg/m<sup>2</sup>/dose over 100 minutes on day 1 (in combination with oxaliplatin); repeat cycle every 14 days (Geoerger 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Dosage reductions for toxicity (Geoerger 2011): 800 mg/m<sup>2</sup>/dose over 80 minutes if grade 3/4 nonhematological toxicity, grade 4 neutropenia with documented infection or lasting &gt;7 days, grade 3/4 thrombocytopenia lasting &gt;7 days or requiring platelets during &gt;7 days, or delay of next cycle &ge;14 days; if necessary dose could be reduced a second time to 600 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Germ cell tumor, refractory:</b> Limited data available: Adolescents &ge;16 years: IV: 1,200 mg/m<sup>2</sup>/dose over 30 minutes on days 1, 8, and 15; repeat cycle every 28 days for up to 6 cycles (Einhorn 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, metastatic:</b> IV: 1,250 mg/m<sup>2</sup> over 30 minutes on days 1 and 8; repeat cycle every 21 days (in combination with paclitaxel)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-small cell lung cancer, locally advanced or metastatic:</b> IV: 1,000 mg/m<sup>2</sup> over 30 minutes on days 1, 8, and 15; repeat cycle every 28 days <b>or</b> 1,250 mg/m<sup>2</sup> over 30 minutes on days 1 and 8; repeat cycle every 21 days in combination with cisplatin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ovarian cancer, advanced:</b> IV: 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pancreatic cancer, locally advanced or metastatic:</b> IV: Initial: 1,000 mg/m<sup>2</sup> over 30 minutes once weekly for up to 7 weeks followed by 1 week of rest; then 1,000 mg/m<sup>2</sup> once weekly for 3 weeks out of every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for renal impairment:</b> Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution in patients with preexisting renal dysfunction. Discontinue if severe renal toxicity or hemolytic uremic syndrome (HUS) occur during gemcitabine treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following adjustments have been made by some clinicians (Janus 2010; Li 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to severe renal impairment: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD with hemodialysis: Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment:</b> Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Discontinue if severe hepatotoxicity occurs during treatment with gemcitabine. The following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transaminases elevated (with normal bilirubin): No adjustment required (Venook 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum bilirubin &gt;1.6 mg/dL: Use initial dose of 800 mg/m<sup>2</sup>; may escalate if tolerated (Ecklund 2005; Floyd 2006; Venook 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hematologic toxicity:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Nonhematologic toxicity (all indications):</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hold or decrease gemcitabine dose by 50% for the following: Severe (grade 3 or 4) nonhematologic toxicity until resolved (excludes nausea, vomiting, or alopecia [no dose modifications recommended])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Permanently discontinue gemcitabine for any of the following: Unexplained dyspnea (or other evidence of severe pulmonary toxicity), severe hepatotoxicity, hemolytic uremic syndrome (HUS), capillary leak syndrome (CLS), posterior reversible encephalopathy syndrome (PRES)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Hematologic toxicity:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Breast cancer: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 1:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Absolute granulocyte count (AGC) &ge;1,500/mm<sup>3</sup> and platelet count &ge;100,000/mm<sup>3</sup>: Administer 100% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC &lt;1,500/mm<sup>3</sup> or platelet count &lt;100,000/mm<sup>3</sup>: Hold dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 8:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC &ge;1,200/mm<sup>3</sup> and platelet count &gt;75,000/mm<sup>3</sup>: Administer 100% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC 1,000 to 1,199/mm<sup>3</sup> or platelet count 50,000 to 75,000/mm<sup>3</sup>: Administer 75% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC 700 to 999/mm<sup>3</sup> and platelet count &ge;50,000/mm<sup>3</sup>: Administer 50% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC &lt;700/mm<sup>3</sup> or platelet count &lt;50,000/mm<sup>3</sup>: Hold dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Non-small cell lung cancer (cisplatin dosage may also require adjustment): </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AGC &ge;1,000/mm<sup>3</sup> and platelet count &ge;100,000/mm<sup>3</sup>: Administer 100% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AGC 500 to 999/mm<sup>3</sup> or platelet count 50,000 to 99,999/mm<sup>3</sup>: Administer 75% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AGC &lt;500/mm<sup>3</sup> or platelet count &lt;50,000/mm<sup>3</sup>: Hold dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Ovarian cancer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 1:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC &ge;1,500/mm<sup>3</sup> and platelet count &ge;100,000/mm<sup>3</sup>: Administer 100% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC &lt;1,500/mm<sup>3</sup> or platelet count &lt;100,000/mm<sup>3</sup>: Delay treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 8:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC &ge;1,500/mm<sup>3</sup> and platelet count &ge;100,000/mm<sup>3</sup>: Administer 100% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC 1,000 to 1,499/mm<sup>3</sup> or platelet count 75,000 to 99,999/mm<sup>3</sup>: Administer 50% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AGC &lt;1,000/mm<sup>3</sup> or platelet count &lt;75,000/mm<sup>3</sup>: Hold dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hematologic toxicity in previous cycle (dosing adjustment for subsequent cycles):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial occurrence: AGC &lt;500/mm<sup>3</sup> for &gt;5 days, AGC &lt;100/mm<sup>3</sup> for &gt;3 days, febrile neutropenia, platelet count &lt;25,000/mm<sup>3</sup>, or cycle delay &gt;1 week due to toxicity: Permanently reduce gemcitabine to 800 mg/m<sup>2</sup> on days 1 and 8</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Subsequent occurrence: AGC &lt;500/mm<sup>3</sup> for &gt;5 days, AGC &lt;100/mm<sup>3</sup> for &gt;3 days, neutropenic fever, platelet count &lt;25,000/mm<sup>3</sup>, or cycle delay &gt;1 week due to toxicity: Permanently reduce gemcitabine to 800 mg/m<sup>2</sup> and administer on day 1 only</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Pancreatic cancer: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AGC &ge;1,000/mm<sup>3</sup> and platelet count &ge;100,000/mm<sup>3</sup>: Administer 100% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AGC 500 to 999/mm<sup>3</sup> or platelet count 50,000 to 99,999/mm<sup>3</sup>: Administer 75% of full dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AGC &lt;500/mm<sup>3</sup> or platelet count &lt;50,000/mm<sup>3</sup>: Hold dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112464\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; based on experience in adult patients, use with caution in patients with preexisting renal dysfunction; discontinue if severe renal toxicity or hemolytic uremic syndrome (HUS) occur during gemcitabine treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112465\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Based on experience in adult patients, discontinue if severe hepatotoxicity occurs during treatment with gemcitabine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175347\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">see &quot;Gemcitabine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Prolongation of the infusion duration &gt;60 minutes and administration more frequently than once weekly have been shown to increase toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Breast cancer (metastatic):</b> IV: 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with paclitaxel) <b>or</b> (off-label dosing; as a single agent) 800 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 of a 28-day treatment cycle (Carmichael 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (inoperable, locally advanced, or metastatic):</b> IV: 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15; repeat cycle every 28 days (in combination with cisplatin) <b>or</b> 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) <b>or</b> (off-label dosing/combination) 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin) for up to 4 cycles (Gr&oslash;nberg 2009) <b>or</b> (off-label combination) 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15; repeat cycle every 28 days (in combination with carboplatin) for up to 4 cycles (Danson 2003) <b>or</b> (off-label combination) 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) for 8 cycles (Pujol 2005) <b>or</b> (off-label combination) 1,000 mg/m<sup>2</sup> days 1, 8, and 15; repeat cycle every 28 days (in combination with vinorelbine) for 6 cycles (Greco 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer (advanced):</b> IV: 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin) <b>or</b> (off-label dosing; as a single agent) 1,000 mg/m<sup>2</sup> over 30 to 60 minutes days 1 and 8; repeat cycle every 21 days (Mutch 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatic cancer (locally advanced or metastatic):</b> IV: Initial: 1,000 mg/m<sup>2</sup> over 30 minutes once weekly for 7 weeks followed by 1 week rest; then once weekly for 3 weeks out of every 4 weeks <b>or </b> (off-label combinations) 1,000 mg/m<sup>2</sup> over 30 minutes weekly for up to 7 weeks followed by 1 week rest; then weekly for 3 weeks out of every 4 weeks (in combination with erlotinib) (Moore 2007) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (in combination with capecitabine) (Cunningham 2009) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 15 every 28 days (in combination with cisplatin) (Heinemann 2006) <b>or</b> 1,000 mg/m<sup>2</sup> infused at 10 mg/m<sup>2</sup>/minute every 14 days (in combination with oxaliplatin) (Louvet 2005) <b>or</b> 1,000 mg/m<sup>2</sup> days 1, 8, and 15 every 28 days (in combination with paclitaxel [protein bound]) (Von Hoff 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pancreatic cancer (adjuvant therapy) (off-label use):</i> IV: 1,000 mg/m<sup>2</sup> on days 1, 8 and 15 every 28 days (in combination with capecitabine) for 6 cycles beginning within 12 weeks of resection (Neoptolemos 2017). American Society of Clinical Oncology guidelines recommend initiating within 8 weeks of resection (ASCO [Khorana 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bladder cancer (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Advanced or metastatic:</i> IV: 1,000 mg/m<sup>2</sup> over 30 to 60 minutes days 1, 8, and 15; repeat cycle every 28 days (in combination with cisplatin) (von der Maase 2000) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin) until disease progression or unacceptable toxicity (De Santis 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Transitional cell carcinoma (refractory):</i> Intravesicular instillation: 2,000 mg (in 100 mL NS; retain for 1 hour) twice weekly for 3 weeks; repeat cycle every 4 weeks for at least 2 cycles (Dalbagni 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical cancer, recurrent or persistent (off-label use):</b> IV: 1,000 mg/m<sup>2</sup> days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) (Monk 2009) <b>or</b> 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) (Burnett 2000) <b>or</b> 800 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15; repeat cycle every 28 days (as a single-agent) (Schilder 2005) <b>or</b> 800 mg/m<sup>2</sup> days 1 and 8; repeat cycle every 28 days (in combination with cisplatin) (Brewer 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Head and neck cancer: nasopharyngeal, advanced or metastatic (off-label use):</b> IV: 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (Zhang 2008) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days (in combination with vinorelbine) (Chen 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatobiliary cancer, advanced (off-label use):</b> IV: 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) (Valle 2010) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with capecitabine) (Knox 2005) <b>or</b> 1,000 mg/m<sup>2</sup> infused at 10 mg/m<sup>2</sup>/minute every 2 weeks (in combination with oxaliplatin) (Andre 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma, relapsed (off-label use):</b> IV: 1,000 mg/m<sup>2</sup> (800 mg/m<sup>2</sup> for post-transplant patients) over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with vinorelbine and doxorubicin liposomal) (Bartlett 2007) <b>or</b> 800 mg/m<sup>2</sup> days 1 and 4; repeat cycle every 21 days (in combination with ifosfamide, mesna, vinorelbine, and prednisolone) (Santoro 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant pleural mesothelioma (off-label use; in combination with cisplatin):</b> IV: 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8 and 15 every 28 days for up to 6 cycles (Nowak 2002) <b>or</b> 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days for up to 6 cycles (van Haarst 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphoma, refractory (off-label use):</b> IV: 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin and dexamethasone) (Crump 2004) <b>or</b> 1,000 mg/m<sup>2</sup> every 15 to 21 days (in combination with oxaliplatin and rituximab) (Lopez 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sarcomas (off-label uses):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Ewing sarcoma, refractory:</i> 675 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Navid 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Osteosarcoma, refractory:</i> 675 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Navid 2008) <b>or</b> 1,000 mg/m<sup>2</sup> weekly for 7 weeks followed by 1 week rest; then weekly for 3 weeks out of every 4 weeks (Merimsky 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Soft tissue sarcoma, advanced:</i> 800 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with vinorelbine) (Dileo 2007) <b>or</b> 675 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Leu 2004) <b>or</b> 900 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Maki 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Small cell lung cancer, refractory or relapsed (off-label use):</b> IV: 1,000 to 1,250 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (as a single agent) (Masters 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Testicular cancer, refractory germ cell (off-label use):</b> IV: 1,000 to 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days (in combination with oxaliplatin) (DeGiorgi 2006; Kohllmannsberger 2004; Pectasides 2004) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days for up to 6 cycles (in combination with paclitaxel) (Hinton 2002) <b>or</b> 800 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days (in combination with oxaliplatin and paclitaxel) (Bokemeyer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Unknown-primary, adenocarcinoma (off-label use):</b> IV: 1,250 mg/m<sup>2</sup> days 1 and 8 every 21 days (in combination with cisplatin) (Culine 2003; Gross-Goupil 2012) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days for up to 6 cycles (in combination with docetaxel) (Pouessel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uterine cancer (off-label use):</b> IV: 900 mg/m<sup>2</sup> over 90 minutes days 1 and 8 every 21 days (in combination with docetaxel) (Hensley 2008) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (Look 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990810\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution in patients with pre-existing renal dysfunction. Discontinue if severe renal toxicity or hemolytic uremic syndrome (HUS) occur during gemcitabine treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild-to-severe renal impairment: No dosage adjustment necessary (Janus 2010; Li 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD (on hemodialysis): Hemodialysis should begin 6 to 12 hours after gemcitabine infusion (Janus 2010; Li 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988014\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Discontinue if severe hepatotoxicity occurs during gemcitabine treatment. The following adjustments have been reported:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transaminases elevated (with normal bilirubin): No dosage adjustment necessary (Venook 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum bilirubin &gt;1.6 mg/dL: Use initial dose of 800 mg/m<sup>2</sup>; may escalate if tolerated (Ecklund 2005; Floyd 2006; Venook 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175320\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/5.26 mL (5.26 mL); 200 mg/2 mL (2 mL); 1 g/10 mL (10 mL); 1 g/26.3 mL (26.3 mL); 1.5 g/15 mL (15 mL); 2 g/20 mL (20 mL); 2 g/52.6 mL (52.6 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/5.26 mL (5.26 mL); 1 g/26.3 mL (26.3 mL); 2 g/52.6 mL (52.6 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gemzar: 200 mg (1 ea); 1 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg (1 ea); 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg (1 ea); 1 g (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175305\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016304\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">IV: Infuse over 30 minutes per manufacturer; however, for other protocols and uses, infusion times may vary (refer to specific protocols). Prolongation of the infusion time &gt;60 minutes has been shown to prolong gemcitabine's half-life and increase toxicity in adults; gemcitabine has been administered in adults utilizing a fixed-dose rate (FDR) of 10 mg/m<sup>2</sup>/minute; prolonged infusion times increase the accumulation of the active metabolite, gemcitabine triphosphate, optimizing the pharmacokinetics (Ko 2006; Tempero 2003); patients who receive gemcitabine FDR experience more grade 3/4 hematologic toxicity (Ko 2006; Poplin 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132601\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).    </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175336\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lyophilized powder:</i> Store intact vials at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Reconstituted vials are stable for 24 hours at room temperature. Do not refrigerate (may form crystals).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Solution for injection:</i> Varies by manufacturer; refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solutions diluted for infusion in NS are stable for 24 hours at room temperature. Do not refrigerate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016263\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of locally advanced, inoperable (stage IIIA or IIIB), or metastatic (stage IV) non-small cell lung cancer (NSCLC), metastatic breast cancer, and advanced relapsed ovarian cancer as part of combination therapy (FDA approved in adults); treatment of locally advanced or metastatic pancreatic cancer as a single agent (FDA approved in adults); has also been used in the treatment of refractory solid tumors (including brain tumors), refractory or relapsed sarcomas (including Ewing sarcoma, osteosarcoma), refractory or relapsed Hodgkin lymphoma, and refractory germ cell tumors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175393\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Gemcitabine may be confused with gemtuzumab</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Gemzar may be confused with Zinecard</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Multiple concentrations: Gemcitabine is available in multiple formulations and concentrations; verify product and concentration prior to admixture to assure appropriate dose preparation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">In Canada, gemcitabine is available as a concentrated solution for injection in different strengths (38 mg/mL and 40 mg/mL), and a powder for reconstitution (final concentration of 38 mg/mL after reconstitution). Verify product concentration prior to preparation for administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175389\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions reported for single-agent use of gemcitabine only; bone marrow depression is the dose-limiting toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drowsiness, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea and vomiting, stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, hemorrhage, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea, flu-like symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening (reported with single-agent use or with combination therapy): Adult respiratory distress syndrome, anaphylactoid reaction, anorexia, arthralgia, bullous skin disease, capillary leak syndrome, cardiac arrhythmia, cardiac failure, cellulitis, cerebrovascular accident (Kuenen 2002), constipation, desquamation, digital vasculitis, gangrene of skin or other tissue, hemolytic-uremic syndrome, hepatic failure, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatotoxicity (rare), hyperglycemia, hypertension, hypocalcemia, hypotension, increased gamma-glutamyl transferase, interstitial pneumonitis, myocardial infarction, neuropathy, petechiae (Nishijima 2013; Zupancic 2007), pruritus (Curtis 2014), pulmonary edema, pulmonary fibrosis, radiation recall phenomenon, renal failure, respiratory failure, reversible posterior leukoencephalopathy syndrome, sepsis, supraventricular cardiac arrhythmia, thrombotic thrombocytopenic purpura (Nishijima 2013; Zupancic 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175327\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gemcitabine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175309\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: May cause bone marrow suppression (neutropenia, thrombocytopenia, and anemia); myelosuppression is generally the dose-limiting toxicity and is increased when used in combination with other chemotherapy. Monitor blood counts; dosage adjustments are frequently required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Capillary leak syndrome: Capillary leak syndrome (CLS) with serious consequences has been reported, both with single-agent gemcitabine and with combination chemotherapy; discontinue if CLS develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic uremic syndrome: Hemolytic uremic syndrome (HUS) has been reported; may lead to renal failure and dialysis (including fatalities); monitor for evidence of anemia with microangiopathic hemolysis (elevation of bilirubin or LDH, reticulocytosis, severe thrombocytopenia, and/or renal failure) and monitor renal function at baseline and periodically during treatment. Permanently discontinue if HUS or severe renal impairment occurs; renal failure may not be reversible despite discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Serious hepatotoxicity (including liver failure and death) has been reported (when used alone or in combination with other hepatotoxic medications); use in patients with hepatic impairment (history of cirrhosis, hepatitis, or alcoholism) or in patients with hepatic metastases may lead to exacerbation of hepatic impairment. Monitor hepatic function at baseline and periodically during treatment; consider dose adjustments with elevated bilirubin; discontinue if severe liver injury develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Posterior reversible encephalopathy syndrome: Posterior reversible encephalopathy syndrome (PRES) has been reported, both with single-agent therapy and with combination chemotherapy. PRES may manifest with blindness, confusion, headache, hypertension, lethargy, seizure, and other visual and neurologic disturbances. If PRES diagnosis is confirmed (by MRI), discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Pulmonary toxicity, including adult respiratory distress syndrome, interstitial pneumonitis, pulmonary edema, and pulmonary fibrosis, has been observed; may lead to respiratory failure (some fatal) despite discontinuation. Onset for symptoms of pulmonary toxicity may be delayed up to 2 weeks beyond the last dose. Discontinue for unexplained dyspnea (with or without bronchospasm) or other evidence of pulmonary toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy recipients: Not indicated for use with concurrent radiation therapy; radiation toxicity, including tissue injury, severe mucositis, esophagitis, or pneumonitis, has been reported with concurrent and nonconcurrent administration; has radiosensitizing activity when gemcitabine and radiation therapy are given together or &le;7 days apart; radiation recall may occur when gemcitabine and radiation therapy are given &gt;7 days apart.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion duration/frequency: Prolongation of the infusion duration &gt;60 minutes or more frequent than weekly dosing have been shown to alter the half-life and increase toxicity (hypotension, flu-like symptoms, myelosuppression, weakness). A fixed-dose rate (FDR) infusion rate of 10 mg/m<sup>2</sup>/minute has been studied in adults in order to optimize the pharmacokinetics (off-label); prolonged infusion times increase the intracellular accumulation of the active metabolite, gemcitabine triphosphate (Ko 2006; Tempero 2003). Patients who receive gemcitabine FDR experience more grade 3/4 hematologic toxicity (Ko 2006; Poplin 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple concentrations: Gemcitabine is available in multiple formulations and concentrations; verify product and concentration prior to admixture to assure appropriate dose preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299393\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175314\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13154&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bleomycin: Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): Gemcitabine may increase the serum concentration of Fluorouracil (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Topical): Gemcitabine may increase the serum concentration of Fluorouracil (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Gemcitabine may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175316\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175329\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on the mechanism of action and on findings from animal reproduction studies, gemcitabine may cause fetal harm if administered during pregnancy. Women of reproductive potential should use effective contraception during treatment and for 6 months after the final gemcitabine dose. Men with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016306\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count prior to each dose; monitor renal and hepatic function prior to initial dose and then periodically, bilirubin, LDH, and reticulocyte count; monitor serum electrolytes, including potassium, magnesium, and calcium (when in combination therapy with cisplatin)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175308\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase, cell cycle-specific for the S-phase of the cycle (also blocks cellular progression at G1/S-phase). Gemcitabine is phosphorylated intracellularly by deoxycytidine kinase to gemcitabine monophosphate, which is further phosphorylated to active metabolites gemcitabine diphosphate and gemcitabine triphosphate. Gemcitabine diphosphate inhibits DNA synthesis by inhibiting ribonucleotide reductase; gemcitabine triphosphate incorporates into DNA and inhibits DNA polymerase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175326\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely distributed into tissues; present in ascitic fluid; V<sub>d</sub>: Infusions &lt;70 minutes: 50 L/m<sup>2</sup>; Long infusion times (70 to 285 minutes): 370 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Negligible</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolized intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleoside metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gemcitabine: Infusion time &le;70 minutes: 42 to 94 minutes; infusion time 3 to 4 hours: 4 to 10.5 hours (affected by age and gender)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metabolite (gemcitabine triphosphate), terminal phase: 1.7 to 19.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 30 minutes after completion of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (92% to 98%; primarily as inactive uracil metabolite); feces (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196101\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Geriatric: The lower clearance in elderly patients results in higher concentrations of gemcitabine for any given dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gender: The lower clearance in women results in higher concentrations of gemcitabine for any given dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524622\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gemcitabine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (10 mL): $79.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/26.3 mL (26.3 mL): $53.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 g/15 mL (15 mL): $99.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/20 mL (20 mL): $140.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/52.6 mL (52.6 mL): $107.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/2 mL (2 mL): $52.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5.26 mL (5.26 mL): $10.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Gemcitabine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $56.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $123.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (1): $11.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Gemzar Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $889.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (1): $177.83</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175330\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abine (AR);</li>\n      <li>Bigemax (VN);</li>\n      <li>Citabol (ID);</li>\n      <li>Cytogem (ID);</li>\n      <li>DBL (TW);</li>\n      <li>Gembine (KR);</li>\n      <li>Gembio (PH);</li>\n      <li>Gemcetin (BD);</li>\n      <li>Gemcibine (KR);</li>\n      <li>Gemcikal (ID, PH);</li>\n      <li>Gemcimax (TH);</li>\n      <li>Gemcit (BR, KR, LK, PE, PH, TH);</li>\n      <li>Gemcite (IN);</li>\n      <li>Gemezar (JO);</li>\n      <li>Gemflor (TW);</li>\n      <li>Gemhope (PH);</li>\n      <li>Gemita (LK, PH, SG, TH, TW);</li>\n      <li>Gemmis (TW);</li>\n      <li>Gemoxen (BD);</li>\n      <li>Gemresec (SG);</li>\n      <li>Gemtan (KR);</li>\n      <li>Gemtavis (ID);</li>\n      <li>Gemtero (SG, TH, ZW);</li>\n      <li>Gemtin (TH);</li>\n      <li>Gemtra (KR);</li>\n      <li>Gemtro (AR);</li>\n      <li>Gemxit (MX);</li>\n      <li>Gemzar (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BO, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, DO, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, HU, ID, IL, IS, IT, KE, KR, KW, LB, LK, LR, LT, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, TH, TN, TR, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Gercizar (LB);</li>\n      <li>Getanosan (ID);</li>\n      <li>Gezt (LB, PY);</li>\n      <li>Gitrabin (HK, HR, PH, RO, SG);</li>\n      <li>Hemtero (UA);</li>\n      <li>Hemzar (UA);</li>\n      <li>Meditabine (IL);</li>\n      <li>Oncogem (LB);</li>\n      <li>Oncoril (LK);</li>\n      <li>Pamigen (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Tsytohem (UA);</li>\n      <li>Zarbin (MX);</li>\n      <li>Zefei (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span><span class=\"doi\">10.1200/JCO.2010.34.4614</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cole PD, Schwartz CL, Drachtman RA, et al, &quot;Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report,&quot; <i>J Clin Oncol</i>, 2009, 27(9):1456-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19224841/pubmed\" target=\"_blank\" id=\"19224841\">19224841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eklund JW, Trifilio S, and Mulcahy MF, &quot;Chemotherapy Dosing in the Setting of Liver Dysfunction,&quot; <i>Oncology (Williston Park)</i>, 2005, 19(8):1057-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16131047/pubmed\" target=\"_blank\" id=\"16131047\">16131047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Einhorn LH, Stender MJ, and Williams SD, &quot;Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors,&quot; <i>J Clin Oncol</i>, 1999, 17(2):509-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10080592/pubmed\" target=\"_blank\" id=\"10080592\">10080592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &quot;Hepatotoxicity of Chemotherapy,&quot; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geoerger B, Chisholm J, Le Deley MC, et al, &quot;Phase II Study of Gemcitabine Combined With Oxaliplatin in Relapsed or Refractory Paediatric Solid Malignancies: An Innovative Therapy for Children With Cancer European Consortium Study,&quot; <i>Eur J Cancer</i>, 2011, 47(2):230-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20943374/pubmed\" target=\"_blank\" id=\"20943374\">20943374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartmann C, Weinel P, Schmid H, et al, &quot;Oxaliplatin, Irinotecan, and Gemcitabine: A Novel Combination in the Therapy of Progressed, Relapsed, or Refractory Tumors in Children,&quot; <i>J Pediatr Hematol Oncol</i>,  2011, 33(5):344-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21572345/pubmed\" target=\"_blank\" id=\"21572345\">21572345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, et al, &quot;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&quot; <i>Ann Oncol</i>, 2010, 21(7):1395-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ko AH, Dito E, Schillinger B, et al, &quot;Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas,&quot; <i>J Clin Oncol</i>, 2006, 24(3):379-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16344320/pubmed\" target=\"_blank\" id=\"16344320\">16344320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li YF, Fu S, Hu W, et al, &quot;Systemic Anticancer Therapy in Gynecological Cancer Patients With Renal Dysfunction,&quot; <i>Int J Gynecol Cancer</i>, 2007, 17(4):739-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17309673/pubmed\" target=\"_blank\" id=\"17309673\">17309673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mora J, Cruz CO, Parareda A, et al, &quot;Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel,&quot; <i>J Pediatr Hematol Oncol</i>, 2009, 31(10):723-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19727011/pubmed\" target=\"_blank\" id=\"19727011\">19727011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navid F, Willert JR, McCarville MB, et al, &quot;Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma,&quot; <i>Cancer</i>, 2008, 113(2):419-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/18484657/pubmed\" target=\"_blank\" id=\"18484657\">18484657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozkaynak MF and Jayabose S, &quot;Gemcitabine and Vinorelbine as a Salvage Regimen for Relapse in Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation,&quot; <i>Pediatr Hematol Oncol</i>, 2004, 21(2):107-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15160509/pubmed\" target=\"_blank\" id=\"15160509\">15160509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poplin E, Feng Y, Berlin J, et al, &quot;Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (Fixed-Dose Rate Infusion) Compared With Gemcitabine (30-Minute Infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group,&quot; <i>J Clin Oncol</i>, 2009, 27(23):3778-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19581537/pubmed\" target=\"_blank\" id=\"19581537\">19581537</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reid JM, Qu W, Safgren SL, et al, &quot;Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors,&quot; <i>J Clin Oncol</i>, 2004, 22(12):2445-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15197207/pubmed\" target=\"_blank\" id=\"15197207\">15197207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santoro A, Magagnoli M, Spina M, et al, &quot;Ifosfamide, Gemcitabine, and Vinorelbine: A New Induction Regimen for Refractory and Relapsed Hodgkin's Lymphoma,&quot; <i>Haematologica</i>, 2007, 92(1):35-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17229633/pubmed\" target=\"_blank\" id=\"17229633\">17229633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suyan&#305; E, Sucak GT, Ak&#305; &#350;Z, et al, &quot;Gemcitabine and Vinorelbine Combination Is Effective in Both as a Salvage and Mobilization Regimen in Relapsed or Refractory Hodgkin Lymphoma Prior to ASCT,&quot; <i>Ann Hematol</i>, 2011, 90(6):685-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21072518/pubmed\" target=\"_blank\" id=\"21072518\">21072518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tempero M, Plunkett W, Ruiz Van Haperen V, et al, &quot;Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma,&quot; <i>J Clin Oncol</i>, 2003, 21(18):3402-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/12885837/pubmed\" target=\"_blank\" id=\"12885837\">12885837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venook AP, Egorin MJ, Rosner GL, et al, &quot;Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565,&quot; <i>J Clin Oncol</i>, 2000, 18(14):2780-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10894879/pubmed\" target=\"_blank\" id=\"10894879\">10894879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xu Q, Zhang Y, Trissel LA. Physical and chemical stability of gemcitabine hydrochloride solutions. <i>J Am Pharm Assoc (Wash)</i>. 1999;39(4):509-513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10467815/pubmed\" target=\"_blank\" id=\"10467815\">10467815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13154 Version 192.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F175343\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F175344\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1016262\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1016297\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112464\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112465\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F175347\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990810\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988014\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F175320\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F175305\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1016304\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132601\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F175336\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1016263\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F175393\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F175389\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F175327\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F175309\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299393\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F175314\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F175316\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F175329\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1016306\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F175308\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F175326\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196101\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524622\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F175330\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13154|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">Gemcitabine: Drug information</a></li><li><a href=\"topic.htm?path=gemcitabine-patient-drug-information\" class=\"drug drug_patient\">Gemcitabine: Patient drug information</a></li></ul></div></div>","javascript":null}